Duration of adjuvant trastuzumab in HER2 positive breast cancer: Overall and disease free survival results from meta-analyses of randomized controlled trials-Reference-Cited by-同舟云学术

Duration of adjuvant trastuzumab in HER2 positive breast cancer: Overall and disease free survival results from meta-analyses of randomized controlled trials

Published:2017-11 Issue: Volume:60 Page:18-23
ISSN:0305-7372
Container-title:Cancer Treatment Reviews
language:en
Short-container-title:Cancer Treatment Reviews

Author:

Gyawali Bishal,Niraula Saroj

Publisher

Elsevier BV

Subject

Radiology Nuclear Medicine and imaging,Oncology,General Medicine

Reference26 articles.

1. The genomic and transcriptomic architecture of 2,000 breast tumours reveals novel subgroups;Curtis;Nature,2012

2. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer;Piccart-Gebhart;New Engl J Med,2005

3. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer;Romond;New Engl J Med,2005

4. Adjuvant trastuzumab in HER2-positive breast cancer;Slamon;New Engl J Med,2011

5. 2 years versus 1 year of adjuvant trastuzumab for HER2-positive breast cancer (HERA): an open-label, randomised controlled trial;Goldhirsch;Lancet,2013

Cited by 33 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. What Powers Trastuzumab's Cardiotoxicity? Decoding Mitochondrial-Related Gene Expression Through Integrative Review and Meta-Analysis in Cardiomyocytes;OMICS: A Journal of Integrative Biology;2024-03-01

2. Effects of clinical treatment decisions on long-term survival outcomes of locally advanced breast cancer with different molecular subtypes based on the SEER database;2023-07-12

3. Three-Year Outcomes Following Permissive Cardiotoxicity in Patients on Trastuzumab;The Oncologist;2023-04-24

4. Cardiotoxicity among socioeconomically marginalized breast cancer patients;Breast Cancer Research and Treatment;2022-08-15

5. Cardioprotection of High-Risk Individuals;Heart Failure Clinics;2022-07